Skip to Main Content

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Once again, our agenda is rather modest. We hope to catch up on our reading, spend time with our shortest person, and attend to sundry chores. And what about you? This may be a good time to tune out the world and take a few naps or, if you insist, catch up on the dizzying array of events thanks to the recent changing of the guard. Or maybe this is a good time to plan the rest of your life. Well, whatever you do, have a good time, but be safe. Enjoy, and see you soon …

Roche may have arrived to market with its Tecentriq immunotherapy drug months after rivals, but the medicine is grabbing market share as a second-line treatment for non-small cell lung cancer, Reuters reports. “Most of our erosion in second line has been attributable to” Tecentriq, Murdo Gordon, Bristol-Myers’s chief commercial officer, told analysts. This is one reason why Bristol-Myers cut its 2017 earnings forecast.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!